✦ LIBER ✦

Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines: Results From the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) Trial

✍ Scribed by Sanjit S. Jolly; David P. Faxon; Keith A.A. Fox; Rizwan Afzal; William E. Boden; Petr Widimsky; P. Gabriel Steg; Vicent Valentin; Andrez Budaj; Christopher B. Granger; Campbell D. Joyner; Susan Chrolavicius; Salim Yusuf; Shamir R. Mehta

Book ID: 119268293
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 847 KB
Volume: 54
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2009.03.062

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and Safety of Fondaparinux Vers

Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results From the OASIS-5 Trial

✍ Shamir R. Mehta; Christopher B. Granger; John W. Eikelboom; Jean-Pierre Bassand; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 609 KB

Fondaparinux versus Enoxaparin in non–ST

Fondaparinux versus Enoxaparin in non–ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial

✍ Mark J. Sculpher; Greta Lozano-Ortega; Jennifer Sambrook; Stephen Palmer; Orges 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 225 KB

Design and rationale of the MICHELANGELO

Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 758 KB

Safety and Efficacy of Bivalirudin With

Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial

✍ Harvey D. White; E. Magnus Ohman; A. Michael Lincoff; Michel E. Bertrand; Antoni 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 571 KB

Randomized evaluation of the efficacy of

Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial

✍ David H. Fitchett; Anatoly Langer; Paul W. Armstrong; Mary Tan; Aurora Mendelsoh 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Efficacy and safety of enoxaparin compar

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial

✍ Harvey D. White; Neal S. Kleiman; Kenneth W. Mahaffey; Yuliya Lokhnygina; Karen 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 333 KB